智通财经APP获悉，辉瑞(PFE.US)与安斯泰来公司日前宣布，将在美国临床肿瘤学会泌尿生殖系统癌症研讨会(ASCO GU)上，公布3期临床试验EV-302的长期随访结果。这项研究评估了抗体偶联药物Padcev(enfortumab vedotin)与Keytruda联用，治疗既往未接受治疗的局部晚期或转移性尿路上皮癌(la/mUC)患者的效果。结果显示，在中位随访时间为29.1个月时，这一组合疗法的总生存期(OS)和无进展生存期(PFS)获益持续保持。
结果显示，与化疗相比，Padcev加Keytruda可将患者死亡风险降低49%(HR=0.51，95% CI：0.43–0.61)。联合治疗组的中位OS为33.8个月，而化疗组为15.9个月。所有预先设定的亚组均观察到了OS的获益。此外，该联合方案还将疾病进展或死亡的风险降低52%(HR=0.48，95% CI：0.41–0.57)。联合治疗组的中位PFS为12.5个月，而化疗组为6.3个月。安全性特征与以往结果一致，未发现新的安全问题。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.